For example, schizophrenia GWAS studies have implicated genes that are targets of compounds with approved indications, such as voltage-gated calcium channels (e.g. CACNA1C, CACNB2 and CACNA1L); pharmaceutical compounds that are antagonists or activators for these calcium channels have been approved for the treatment hypertension, arrhythmia or epilepsy [78]. The gene discussed is CACNA1C; the disease is Hypertension.